Caravella; Justin A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Caravella; Justin A..The latest application filed is for "inhibiting deubiquitinase usp25 and usp28".

Company Profile

8.10.14

Caravella; Justin A. - Cambridge MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors Grant 11,325,917 - Guerin , et al. May 10, 2	2022-05-10
Purinones as ubiquitin-specific protease 1 inhibitors Grant 11,161,848 - Buckmelter , et al. November 2, 2	2021-11-02
Inhibiting Deubiquitinase Usp25 And Usp28 App 20210179628 - GUERIN; David J. ; et al.	2021-06-17
Thienopyrazine Carboxamides As Ubiquitin-specific Protease Inhibitors App 20210047343 - Guerin; David Joseph ; et al.	2021-02-18
Thienopyridine carboxamides as ubiquitin-specific protease inhibitors Grant 10,913,753 - Guerin , et al. February 9, 2	2021-02-09
Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors Grant 10,889,592 - Guerin , et al. January 12, 2	2021-01-12
Purinones As Ubiquitin-specific Protease 1 Inhibitors App 20200079776 - Buckmelter; Alexandre Joseph ; et al.	2020-03-12
Thienopyridine Carboxamides as Ubiquitin-Specific Protease Inhibitors App 20200017525 - Guerin; David Joseph ; et al.	2020-01-16
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors App 20190359628 - Guerin; David Joseph ; et al.	2019-11-28
Purinones as ubiquitin-specific protease 1 inhibitors Grant 10,399,980 - Buckmelter , et al. Sep	2019-09-03
Purinones as ubiquitin-specific protease 1 inhibitors Grant 10,189,841 - Buckmelter , et al. Ja	2019-01-29
Anti-blood Dendritic Cell Antigen 2 Antibodies And Uses Thereof App 20180362652 - Caravella; Justin A. ; et al.	2018-12-20
Purinones As Ubiquitin-specific Protease 1 Inhibitors App 20180339986 - Buckmelter; Alexandre Joseph ; et al.	2018-11-29
Anti-blood dendritic cell antigen 2 antibodies and uses thereof Grant 9,902,775 - Caravella , et al. February 27, 2	2018-02-27
Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors Grant 9,902,728 - Ioannidis , et al. February 27, 2	2018-02-27
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto Grant 9,738,707 - Taylor , et al. August 22, 2	2017-08-22
Purinones As Ubiquitin-specific Protease 1 Inhibitors App 20170145012 - Buckmelter; Alexandre Joseph ; et al.	2017-05-25
Pyrrolo And Pyrazolopyrimidines As Ubiquitin-specific Protease 7 Inhibitors App 20160185785 - Ioannidis; Stephanos ; et al.	2016-06-30
Anti-Blood Dendritic Cell Antigen 2 Antibodies And Uses Thereof App 20150299325 - CARAVELLA; Justin A. ; et al.	2015-10-22
Heterodimeric Fc Regions, Binding Molecules Comprising Same, And Methods Relating Thereto App 20140341906 - Taylor; Frederick R. ; et al.	2014-11-20
Anti-lymphotoxin Antibodies App 20140079716 - RANGER; Ann M. ; et al.	2014-03-20
Anti-lymphotoxin Antibodies App 20120003235 - Ranger; Ann M. ; et al.	2012-01-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.